Auson Pharmaceutical: Subsidiary Malibawei Tablets Obtains Drug Registration Certificate

Aosekan announcement, its wholly-owned subsidiary Jiangsu Aosekan Pharmaceutical Co., Ltd. recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for maribavir tablets. Maribavir is the world's only marketed drug targeting the pUL97 protein kinase of cytomegalovirus. It is also the world's first and only approved treatment for pediatric patients with refractory/resistant cytomegalovirus infection/disease after transplantation, used to treat hematopoietic stem cell transplant or solid organ transplant recipients who have failed previous treatments in both adults and children with CMV infection and/or disease.